The current worldwide value of drugs and devices for the treatment of obesity stands at $750 million, representing a minor share of the combined potential market expected for these products over the next decade as rates of obesity incidence and prevalence surge and as recognition of its healthcare cost drives development of effective solutions. 
Given the current available treatments, the only effective, long-term treatment for morbid obesity is currently bariatric surgery. Several devices used in bariatric surgery are on the market in either the EU or the
Note: The exhibit illustrates the forecast market for both bariatric surgical devices and obesity drug treatments, representing a “best case scenario” for both segments. Growth is overall driven by burgeoning demand, but the upside for the pharmaceutical segment is much more highly at risk given the uncertainty in drug development (as evidenced by Pfizer’s failure with Rimonabant). Hence, the apparent potential across the two segments can be somewhat deceiving.
The current worldwide value of drugs and devices for the treatment of obesity stands at $750 million, representing a minor share of the combined potential market expected for these products over the next decade as rates of obesity incidence and prevalence surge and as recognition of its healthcare cost drives development of effective solutions. Given the current available treatments, the only effective, long-term treatment for morbid obesity is currently bariatric surgery. Several devices used in bariatric surgery are on the market in either the EU or the US, or both; several others, including second generation gastric banding, are under development. Companies are at work inventing and testing entirely novel products, such as items made to fit into the upper mouth; neurological devices to be applied to the stomach or brain; and innovative ways to perform the surgery.
Note: Exhibit 1 illustrates the forecast market for both bariatric surgical devices and obesity drug treatments, representing a “best case scenario” for both segments. Growth is overall driven by burgeoning demand, but the upside for the pharmaceutical segment is much more highly at risk given the uncertainty in drug development (as evidenced by Pfizer’s failure with Rimonabant). Hence, the apparent potential across the two segments can be somewhat deceiving.
(See MedMarket Diligence report #S825, “Worldwide Market for the Clinical Management of Obesity, 2007.“)
Tags: medtech, obesity, bariatric, lapband
Comments 3
I think, data across regions or price segments would be more interesting. I hardly can imagine company that works on such wide spectre.
Posted 16 May 2008 at 2:39 am ¶The data in the graph is an aggregate, drawn from geographic segmentation including U.S., Europe (by country), Asia/Pacific and Rest of World (from the worldwide obesity report by MedMarket Diligence). Nonetheless there are multinational drug and device companies who operate on a global basis and
Posted 16 May 2008 at 4:46 am ¶I am able to see that Obesity pharmaceutical sales are expected to rise steeply in the forthcoming years! It suggests that the number of people who are going to steer due to the obesity problem would really rise to enormous levels. Great statistics and hints on the rising obesity issues! Thanks for the nice and informative article!
Posted 18 May 2008 at 12:25 am ¶Post a Comment